Jeffrey Dao, Operations & Business Development Officer to present HighTide’s HTD1801 for primary sclerosing cholangitis (PSC) at the World Orphan Drug Congress USA 2019 in Oxon Hill, MD...

[Rockville, Maryland, Dec. 11, 2018] — HighTide Therapeutics, today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9.

[Rockville, Maryland, Nov. 27, 2018] — HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company, announced that the U.S. FDA has granted Fast Track Designation to its investigational new drug, HTD1801...